Abstract
Approximately 50% of neurofibromatosis type 1 (NF1) patients exhibit skeletal pathology, such as premature osteoporosis or pseudoarthroses. Loss of neurofibromin deregulates Ras signal transduction to affect generation of mitogen-activated protein kinase and Akt, both of which have been implicated in parathyroid hormone (PTH) anabolic mechanisms. Our aim was to determine if loss of neurofibromin impaired the anabolic effect of PTH on bone mass. Nf1 heterozygote (Nf1+/−) and wild type (Nf1+/+) mice were treated with recombinant human PTH1–34 or vehicle once daily for 3–28 days. PTH enhanced mRNA expression of c-fos, junB, and fra2 in the distal femur metaphyses of both genotypes; expression of these transcripts was consistently lower in PTH-treated Nf1+/− mice. Despite lowered c-fos expression in Nf1+/− mice, PTH increased bone mass equivalently in both genotypes by 28 days. Ex vivo, Nf1 heterozygosity was associated with increased inducible osteoclasts in PTH-treated bone marrow cells and impairment of the actin stress fiber and cyclic adenosine monophosphate response to PTH in osteoprogenitors. Lower c-fos expression was previously thought to abrogate PTH responsiveness. Our results suggest crosstalk might occur between Ras signal transduction and the protein kinase A pathway in Nf1+/− mice. Ras signal transduction does not appear to be essential for the anabolic actions of PTH on bone. Because PTH was effective in the absence of Nf1, it may offer a useful approach to treat osteoporosis in NF1 patients.
Similar content being viewed by others
References
Riccardi V, Womack JE, Jacks T (1994) Neurofibromatosis and related tumors. Natural occurrence and animal models. Am J Pathol 145: 994–1000
Crawford A, Schorry E (1999) Neurofibromatosis in children: the role of the orthopedist. J Am Acad Orthop Surg 7: 217–230
Vitale M, Guha A, Skaggs D (2002) Orthopedic manifestations of neurofibromatosis in children: an update. Clin Orthop Relat Res 1: 107–118
Gilbert A, Brockman R (1995) Congenital pseudarthrosis of the tibia. Clin Orthop 314: 37–44
Illes T, Halmai V, de Jonge T, Dubousset J (2001) Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12: 823–827
Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, Peltonen J (2005) Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16: 928–936
Yu X, Chen S, Potter OL, Murthy SM, Li J, Pulcini JM, Ohashi N, Winata T, Everett ET, Ingram D, Clapp WD, Hock JM (2005) Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36: 793–802
Elefteriou F, Benson DM, Liu X, Parada L, Karsenty G (2005) Neurofibromin (Nf1) through its expression in osteoblasts, controls bone formation and bone resorption. J Bone Miner Res (suppl 1):S14
McCormick F (1995) Ras signaling and NF1. Curr Opin Genet Dev 5: 51–55
Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW (2001) Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1−/− cells. J Biol Chem 276: 7240–7245
Zhu Y, Ghosh P, Charnay P, Burns D, Parada L (2002) Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296: 920–922
Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW (2000) Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191: 181–188
Lindsay R, Nieves J, Formica C, Henneman C, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350: 550–555
Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M (2002) Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1–34). J Bone Miner Res 17: 2038–2047
Andreassen TT, Fledelius C, Ejersted C, Oxlund H (2001) Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand 72: 304–307
Bollag G, Clapp D, Shih S, Adler F, Zhang Y, Thompson P, Lange B, Freedman M, McCormick F, Jacks T (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. Nat Genet 12: 144–148
Stanislaus D, Yang X, Liang J, Wolfe J, Cain R, Onyia J, Falla N, Marder P, Bidwell J, Queener S, Hock J (2000) In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone, hPTH 1–34 fragment. Bone 27: 209–218
Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P (1999) Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14: 1167–1174
Turner CH, Hsieh YF, Muller R, Bouxsein ML, Baylink DJ, Rosen CJ, Grynpas MD, Donahue LR, Beamer WG (2000) Genetic regulation of cortical and trabecular bone strength and microstructure in inbred strains of mice. J Bone Miner Res 15: 1126–1131
John V, Hock J, Short L, Glasebrook A, Galvin R (1996) A role for CD8+ T-lymphocytes in osteoclast differentiation in vitro. Endocrinology 137: 2457–2463
Onyia J, Miller B, Hulman J, Liang J, Galvin R, Frolik C, Chandrasekhar S, Harvey A, Bidwell J, Herring J, Hock J (1997) Proliferating cells in the primary spongiosa express the osteoblast phenotype in vitro. Bone 20: 93–100
Jerome C, Burr D, Bibber TV, Hock J, Brommage R (2001) Treatment with human parathryoid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28: 150–159
Egan J, Gronowicz G, Rodan G (1991) Parathyroid hormone promotes the disassembly of cytoskeletal actin and myosin in cultured osteoblastic cells: mediation by cyclic AMP. J Cell Biochem 45: 101–111
The I, Hannigan GE, Cowley GS, Reginald S, Zhong Y, Gusella JF, Hariharan IK, Bernards A (1997) Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276: 791–794
Gutmann D, Wu YL, Hedrick NM, Zhu Y, Guha A, Parada LF (2001) Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet 10: 3009–3016
Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, Wenning MJ, Diaz B, Travers JB, Hood A, Marshall M, Williams DA, Clapp DW (2001) Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 194: 57–69
Riccardi V (1992) Neurofibromatosis: phenotype, natural history and pathogenesis. Johns Hopkins University Press, Baltimore
Chen S, Ingram DA, Fisher L, Wenning MJ, Yu X, Hock JM, Clapp DW (2002) NF1 plays an essential role in osteoclasts development and its survival. Blood 100: 81
Aubin JE, Alders E, Heersche JN (1983) A primary role for microfilaments, but not microtubules, in hormone-induced cytoplasmic retraction. Exp Cell Res 143: 439–450
Chen C, Koh A, Zhang NDJ, Keller E, Xiao G, Franceschi R, D’Silva N, McCauley L (2004) Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. J Biol Chem 279: 29121–29129
Fujita T, Meguro T, Fukuyama R, Nakamuta H, Koida M (2002) New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. J Biol Chem 277: 22191–22200
Miao D, Tong X, Chan G, Panda D, McPherson P, Goltzman D (2001) Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem 276: 32204–32212
Swarthout JT, Doggett TA, Lemker JL, Partridge NC (2001) Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent. J Biol Chem 276: 7586–7592
Li J, Duncan RL, Burr DB, Gattone VH, Turner CH (2003) Parathyroid hormone enhances mechanically induced bone formation, possibly involving L-type voltage-sensitive calcium channels. Endocrinology 144: 1226–1233
You J, Reilly GC, Zhen X, Yellowley CE, Chen Q, Donahue HJ, Jacobs CR (2001) Osteopontin gene regulation by oscillatory fluid flow via intracellular calcium mobilization and activation of mitogen-activated protein kinase in MC3T3-E1 osteoblasts. J Biol Chem 276: 13365–13371
Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kucukceylan N, Abdel-Nour M, Gewies A, Peters H, Kaufmann D, Buske A, Tinschert S, Nurnberg P (2000) Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet 66: 790–818
Kano J, Sugimoto T, Kanatani M, Kuroki Y, Tsukamoto T, Fukase M, Chihara K (1994) Second messenger signaling of c-fos gene induction by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells: its role in osteoblast proliferation and osteoclast-like cell formation. J Cell Physiol 161: 358–366
Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K (2005) Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 328: 91–97
Theoleyre S, Wittrant Y, Couillaud S, Vusio P, Berreur M, Dunstan C, Blanchard F, Redini F, Heymann D (2004) Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. Biochim Biophys Acta 1644: 1–7
Onyia J, Miles R, Yang X, Halladay D, HAle J, Glasebrook A, McClure D, Seno G, Churgey L, Chandrasekhar S, Martin T (2000) In vivo demonstration that parathyroid hormone 1–38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 16: 863–871
Acknowledgement
This work was funded by research grants to Drs. J. M. Hock and W. D. Clapp from The Neurofibromatosis Foundation and the U.S. Department of Defense Neurofibromatosis Research Program
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yu, X., Milas, J., Watanabe, N. et al. Neurofibromatosis Type 1 Gene Haploinsufficiency Reduces AP-1 Gene Expression without Abrogating the Anabolic Effect of Parathyroid Hormone. Calcif Tissue Int 78, 162–170 (2006). https://doi.org/10.1007/s00223-005-0201-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-005-0201-x